Kazia Reports 100% Clinical Benefit Rate in Stage IV TNBC; Files Investor Deck for Proposed Offering
KZIA has more than doubled off its 52-week low of $4.86 on elevated volume (4.3× avg).
Summary
Kazia reported 100% clinical benefit in six evaluable Stage IV TNBC patients treated with paxalisib, including one durable complete response, and filed an investor presentation disclosing a proposed equity offering and expansion plans.
Key Events · Product Development and Regulatory · KZIA
-
100% Clinical Benefit in Stage IV TNBC
All six evaluable patients showed clinical benefit: 5 objective responses (1 complete, 4 partial) and 1 stable disease, for an 83% objective response rate.
-
Durable Complete Metabolic Response
A 44-year-old patient achieved a complete metabolic response with no evidence of disease since November 2025, with sustained elimination of CTC clusters and reduction in exhausted T cells.
-
Translational Biomarker Reductions
Median 83% reduction in CTC clusters (range 76–90%) and median 51% reduction in terminally exhausted CD8+ T cells (range 18–97%) across all six patients, with no treatment-related serious adverse events.
-
Financial Position and Proposed Offering
Investor presentation discloses approximately US$46 million cash at 12/31/25 with runway into 2029, no debt, and a proposed equity offering under registration statement File No. 333-294392 with Leerink Partners and Guggenheim Securities.
Analysis · KZIA · Life Sciences
Paxalisib delivered a 100% clinical benefit rate in six evaluable Stage IV triple-negative breast cancer patients, with five objective responses including one durable complete metabolic response ongoing since November 2025 and no treatment-related serious adverse events. Translational data across all six patients showed a median 83% reduction in CTC clusters and a 51% reduction in terminally exhausted T cells, supporting a potentially first-in-class dual mechanism that addresses both metastatic dissemination and immune exhaustion. Against that backdrop, the investor presentation discloses approximately US$46 million in cash with runway into 2029, no debt, and a proposed equity offering under an existing shelf registration — capital that would fund expansion into HR+/HER2- breast cancer, early-stage TNBC, and pMMR colorectal cancer. For a $167 million company, the combination of compelling early efficacy data and a concurrent financing effort makes this a thesis-altering disclosure.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 41.4% of the 432 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KZIA was trading at $13.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $166.8M. The 52-week trading range was $4.86 to $17.40. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.